Pyxis Oncology (PYXS) Cash from Investing Activities (2021 - 2025)

Pyxis Oncology (PYXS) has 5 years of Cash from Investing Activities data on file, last reported at $16.3 million in Q4 2025.

• On a quarterly basis, Cash from Investing Activities fell 39.0% year-over-year to $16.3 million in Q4 2025; TTM through Dec 2025 was $58.9 million, a 621.73% increase from a year earlier, with the FY2025 full-year figure at $58.9 million, up 621.73% from the prior year.
• Cash from Investing Activities for Q4 2025 stood at $16.3 million, up from $11.5 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for PYXS reached as high as $26.7 million in Q4 2024 and fell as low as -$99.4 million in Q1 2023.
• Historically, Cash from Investing Activities has averaged -$2.5 million across 5 years, with a median of -$68500.0 in 2022.
• Across the five-year window, Cash from Investing Activities tumbled 67977.4% in 2023 and soared 382500.0% in 2025, its largest moves.
• Year by year, Cash from Investing Activities stood at -$371000.0 in 2021, then tumbled by 400.81% to -$1.9 million in 2022, then surged by 650.48% to $10.2 million in 2023, then surged by 160.63% to $26.7 million in 2024, then plunged by 39.0% to $16.3 million in 2025.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were $16.3 million in Q4 2025, $11.5 million in Q3 2025, and $15.3 million in Q2 2025.